Ayana Bio uses Ginkgo Bioworks’ cell programming platform to produce high-purity plant and fungal bioactive ingredients for complementary medicines, nutraceuticals, and traditional medicines. The company aims to replace unsustainable harvesting and reduce variability in natural-source ingredients by manufacturing standardized, clean, and reliable bioactives via fermentation. Ayana plans to collaborate with consumer packaged goods brands, supplement makers, specialized nutrition firms, OTC companies, and traditional medicines stakeholders to commercialize these ingredients in convenient forms. The approach targets markets spanning nutrition to herbal medicines, which the article states together represent over $400 billion. Ayana positioned biotechnology as a solution for content standardization, product safety, and sustainable ingredient supply. The company launched with a Series A and is part of Ginkgo’s Platform Ventures portfolio alongside companies like Joyn Bio and Motif FoodWorks.

Total raised

$30M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2021